NICE recommends Enhertu for people with HER2-low advanced breast cancer
Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.
Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.
People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment under draft NICE guidance published today.
Four technology appraisals for type 2 diabetes have been updated, and guidance on 4 further medicines is being withdrawn, as part of NICE's first test of a new way of keeping all its guidance aligned.
Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation today (Thursday, 20 August). The switch could cut the number of injections each patient needs by 85%.
Our annual report and accounts covering April 2025 to March 2026 highlight our key achievements. Find out how we’re delivering against the 10 Year Health plan, and how we’re becoming more relevant, timely, impactful and usable.
A groundbreaking approach to monitoring heart failure patients remotely has reduced unnecessary hospital admissions by 58%, improving patient experience and saving the NHS £4,158 per patient.
Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.
Why should AI be the next topic for NICE Listens? This blog explains why AI should be the next topic for our public engagement programme, which explores the difficult questions that sit behind complex decisions.
